

to: [http://www.archives.gov/federal\\_register/code\\_of\\_federal\\_regulations/ibr\\_locations.html](http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html).

Issued in Kansas City, Missouri, on November 22, 2006.

**Kim Smith,**

*Manager, Small Airplane Directorate, Aircraft Certification Service.*

[FR Doc. E6-20325 Filed 12-1-06; 8:45 am]

**BILLING CODE 4910-13-P**

## DEPARTMENT OF TRANSPORTATION

### Federal Aviation Administration

#### 14 CFR Part 71

[Docket No. FAA-2006-25182; Airspace Docket No. 06-AAL-21]

#### Revision of Class E Airspace; Iliamna, AK

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Final rule; correction.

**SUMMARY:** This action corrects an error in the airspace description contained in a Final Rule that was published in the **Federal Register** on Friday, October 6, 2006 (71 FR 59007). Airspace Docket No. 06-AAL-21.

**DATES:** *Effective Date:* 0901 UTC, January 18, 2007. The Director of the Federal Register approves this incorporation by reference action under title 1, Code of Federal Regulations, part 51, subject to the annual revision of FAA Order 7400.9 and publication of conforming amendments.

**FOR FURTHER INFORMATION CONTACT:** Gary Rolf, AAL-538G, Federal Aviation Administration, 222 West 7th Avenue, Box 14, Anchorage, AK 99513-7587; telephone number (907) 271-5898; fax: (907) 271-2850; e-mail: [gary.ctr.rolf@faa.gov](mailto:gary.ctr.rolf@faa.gov). Internet address: <http://www.alaska.faa.gov/at>.

#### SUPPLEMENTARY INFORMATION:

##### History

**Federal Register** Document E6-16504, Airspace Docket No. 06-AAL-21, published on Friday, October 6, 2006 (71 FR 59007), revised Class E airspace at Iliamna, AK. An error was discovered in the airspace description associated with the directional reference to the 200° bearing from the Iliamna Non-directional Beacon. This action corrects that error by removing it.

##### Correction to Final Rule

■ Accordingly, pursuant to the authority delegated to me, the airspace description of the Class E airspace published in the **Federal Register**,

Friday, October 6, 2006 (71 FR 59007), (FR doc. E6-16504, page 59007, all references to Iliamna) is corrected as follows:

#### § 71.1 [Corrected]

\* \* \* \* \*

#### AAL AK E5 Iliamna, AK [Revised]

Iliamna Airport, AK

(Lat. 59°45'16" N., long. 154°54'39" W.)

Iliamna NDB

(Lat. 59°44'53" N., long. 154°54'35" W.)

That airspace extending upward from 700 feet above the surface within a 6.7-mile radius of the Iliamna Airport and that airspace 4 miles west and 8 miles east of the 200° bearing from the Iliamna NDB extending from the 6.7-mile radius to 16 miles; and that airspace extending upward from 1,200 feet above the surface within an area bounded by lat.60°14'00" N. long. 154°54'00" W., to lat. 59°46'20" N. long. 153°52'00" W., to lat. 59°43'00" N. long. 153°00'00" W., to lat. 59°33'00" N. long. 153°00'00" W., to lat. 59°28'00" N. long. 154°13'00" W., to lat. 59°18'00" N. long. 154°04'00" W., to lat. 59°11'00" N. long. 155°17'00" W., to lat. 59°32'00" N. long. 155°31'00" W., to lat. 59°41'00" N. long. 156°35'00" W., to the point of beginning.

\* \* \* \* \*

Issued in Anchorage, AK, on November 16, 2006.

**Linda J. Couture,**

*Acting Director, Alaska Flight Service Information Office.*

[FR Doc. 06-9516 Filed 12-1-06; 8:45 am]

**BILLING CODE 4910-13-M**

## DEPARTMENT OF TRANSPORTATION

### Federal Aviation Administration

#### 14 CFR Part 71

[Docket No. FAA-2006-25180; Airspace Docket No. 06-AAL-19]

#### Establishment of Class E Airspace; Kokhanok, AK

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Final rule; correction.

**SUMMARY:** This action corrects an error in the location name (Kokhanok) contained in a Final Rule that was published in the **Federal Register** on Tuesday, October 10, 2006 (71 FR 59372). Airspace Docket No. 06-AAL-19.

**DATES:** *Effective Date:* 0901 UTC, November 23, 2006. The Director of the Federal Register approves this incorporation by reference action under title 1, Code of Federal Regulations, part 51, subject to the annual revision of FAA Order 7400.9 and publication of conforming amendments.

**FOR FURTHER INFORMATION CONTACT:** Gary Rolf, AAL-538G, Federal Aviation Administration, 222 West 7th Avenue, Box 14, Anchorage, AK 99513-7587; telephone number (907) 271-5898; fax: (907) 271-2850; e-mail: [gary.ctr.rolf@faa.gov](mailto:gary.ctr.rolf@faa.gov). Internet address: <http://www.alaska.faa.gov/at>.

#### SUPPLEMENTARY INFORMATION:

##### History

**Federal Register** Document 06-8523, Airspace Docket No. 06-AAL-19, published on Tuesday, October 10, 2006 (71 FR 59372), established Class E airspace at Kokhanok, AK. An error was discovered in the spelling of the airport name, Kokhanok. This action corrects that error.

##### Correction to Final Rule

■ Accordingly, pursuant to the authority delegated to me, the airspace description of the Class E airspace published in the **Federal Register**, Tuesday, October 10, 2006 (71 FR 59372), (FR Doc 06-8523, page 59372, all references to Kokhanok) is corrected as follows:

#### § 71.1 [Corrected]

\* \* \* \* \*

#### AAL AK E5 Kokhanok, AK [New]

Kokhanok Airport, AK

(Lat. 59°26'00" N., long. 154°48'09" W.)

That airspace extending upward from 700 feet above the surface within a 6.9-mile radius of the Kokhanok Airport, and that airspace 1 mile north and 1 mile south of the 260° bearing from the Kokhanok Airport extending from the 6.9-mile radius to 8.8 miles west of the Kokhanok Airport, and that airspace extending upward from 1,200 feet above the surface within a 49-mile radius of the Kokhanok Airport.

\* \* \* \* \*

Issued in Anchorage, AK, on November 16, 2006.

**Linda J. Couture,**

*Acting Director, Alaska Flight Service Information Office.*

[FR Doc. 06-9515 Filed 12-1-06; 8:45 am]

**BILLING CODE 4910-13-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### 21 CFR Part 520

#### Oral Dosage Form New Animal Drugs; Sulfamethazine Soluble Powder

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Cross Vetpharm Group Ltd. The ANADA provides for use of sulfamethazine soluble powder to create a solution administered as a drench to swine or cattle, or in the drinking water of chickens, turkeys, swine, or cattle for the treatment of coccidiosis or various bacterial diseases.

**DATES:** This rule is effective December 4, 2006.

**FOR FURTHER INFORMATION CONTACT:** John K. Harshman, Center for Veterinary Medicine (HFV-104), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0169, e-mail: [john.harshman@fda.hhs.gov](mailto:john.harshman@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland, filed ANADA 200-434 that provides for use of SMZ-MED 454 (sulfamethazine sodium) Soluble Powder to create a solution administered as a drench to swine or cattle, or in the drinking water of chickens, turkeys, swine, or cattle for the treatment of coccidiosis or various bacterial diseases. Cross Vetpharm Group Ltd.'s SMZ MED 454 Soluble Powder is approved as a generic copy of Fort Dodge Animal Health, a Division of Wyeth Holdings Corp.'s, SULMET Soluble Powder which was approved under NADA 122-272. The ANADA is approved as of November 3, 2006, and the regulations are amended in 21 CFR 520.2261b to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

FDA has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the

congressional review requirements in 5 U.S.C. 801-808.

#### List of Subjects in 21 CFR Part 520

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

#### PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 520 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

■ 2. Revise § 520.2261b to read as follows:

#### § 520.2261b Sulfamethazine powder.

(a) *Specifications.* A soluble powder composed of 100 percent sulfamethazine sodium.

(b) *Sponsors.* See Nos. 053501 and 061623 in § 510.600(c) of this chapter.

(c) *Related tolerances.* See § 556.670 of this chapter.

(d) *Conditions of use*—(1) *Chickens*—(i) *Amount.* Administer in drinking water to provide 58 to 85 milligrams (mg) per pound (lb) of body weight per day.

(ii) *Indications for use.* For control of infectious coryza (*Haemophilus gallinarum*), coccidiosis (*Eimeria tenella*, *E. necatrix*), acute fowl cholera (*Pasteurella multocida*), and pullorum disease (*Salmonella pullorum*).

(iii) *Limitations.* Add the required dose to that amount of water that will be consumed in 1 day. Consumption should be carefully checked. Have only medicated water available during treatment. Withdraw medication 10 days prior to slaughter for food. Do not medicate chickens producing eggs for human consumption. Treatment of all diseases should be instituted early. Treatment should continue 24 to 48 hours beyond the remission of disease symptoms. Medicated chickens must actually consume enough medicated water which provides the recommended dosages.

(2) *Turkeys*—(i) *Amount.* Administer in drinking water to provide 50 to 124 mg/lb of body weight per day

(ii) *Indications for use.* For control of coccidiosis (*E. meleagridis*, *E. adenoides*).

(iii) *Limitations.* Add the required dose to that amount of water that will be consumed in 1 day. Consumption should be carefully checked. Have only medicated water available during treatment. Withdraw medication 10 days prior to slaughter for food. Do not

medicate turkeys producing eggs for human consumption. Treatment of all diseases should be instituted early. Treatment should continue 24 to 48 hours beyond the remission of disease symptoms. Medicated turkeys must actually consume enough medicated water which provides the recommended dosages.

(3) *Swine*—(i) *Amount.* Administer in drinking water, or as a drench, to provide 108 mg/lb of body weight on the first day and 54 mg/lb of body weight per day on the second, third, and fourth days of administration.

(ii) *Indications for use.* For treatment of porcine colibacillosis (bacterial scours) (*E. coli*), and bacterial pneumonia (*Pasteurella* spp.).

(iii) *Limitations.* Add the required dose to that amount of water that will be consumed in 1 day. Consumption should be carefully checked. Have only medicated water available during treatment. Withdraw medication 15 days prior to slaughter for food. Treatment of all diseases should be instituted early. Treatment should continue 24 to 48 hours beyond the remission of disease symptoms, but not to exceed a total of 5 consecutive days. Medicated swine must actually consume enough medicated water which provides the recommended dosages.

(4) *Cattle*—(i) *Amount.* Administer in drinking water, or as a drench, to provide 108 mg/lb of body weight on the first day and 54 mg/lb of body weight per day on the second, third, and fourth days of administration.

(ii) *Indications for use in beef and nonlactating dairy cattle.* Treatment of bacterial pneumonia and bovine respiratory disease complex (shipping fever complex) (*Pasteurella* spp.), colibacillosis (bacterial scours) (*E. coli*), necrotic pododermatitis (foot rot) (*Fusobacterium necrophorum*), calf diphtheria (*F. necrophorum*), acute mastitis (*Streptococcus* spp.), and acute metritis (*Streptococcus* spp.)

(iii) *Limitations.* Add the required dose to that amount of water that will be consumed in 1 day. Consumption should be carefully checked. Have only medicated water available during treatment. Withdraw medication 10 days prior to slaughter for food. Treatment of all diseases should be instituted early. Treatment should continue 24 to 48 hours beyond the remission of disease symptoms, but not to exceed a total of 5 consecutive days. Medicated cattle must actually consume enough medicated water which provides the recommended dosages.

Dated: November 17, 2006.  
**Stephen F. Sundlof,**  
 Director, Center for Veterinary Medicine.  
 [FR Doc. E6-20404 Filed 12-1-06; 8:45 am]  
 BILLING CODE 4160-01-S

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Part 558**

**New Animal Drugs For Use in Animal Feeds; Florfenicol**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Schering-Plough Animal Health Corp. The NADA provides for the use of a florfenicol Type A medicated article by veterinary feed directive to formulate swine feed used for the control of respiratory disease.

**DATES:** This rule is effective December 4, 2006.

**FOR FURTHER INFORMATION CONTACT:** Joan C. Gotthardt, Center for Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7571, e-mail: joan.gotthardt@fda.hhs.gov.

**SUPPLEMENTARY INFORMATION:** Schering-Plough Animal Health Corp., 556 Morris Ave., Summit, NJ 07901, filed NADA 141-264 that provides for use of NUFLOL (florfenicol), an antibiotic, a Type A medicated article by veterinary feed directive to formulate Type C medicated feeds used for the control of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Streptococcus suis*, and *Bordetella bronchiseptica* in groups of swine in buildings experiencing an outbreak of SRD. The NADA is approved as of November 3, 2006, and the regulations are amended in 21 CFR 558.4 and 558.261 to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for 3 years of marketing exclusivity beginning November 3, 2006.

The agency has determined under 21 CFR 25.33(d)(5) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

**List of Subjects in 21 CFR Part 558**

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

**PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS**

1. The authority citation for 21 CFR part 558 continues to read as follows:

**Authority:** 21 U.S.C. 360b, 371.

2. In paragraph (d) of § 558.4, in the "Category II" table, revise the entry for "Florfenicol" to read as follows:

**§ 558.4 Requirement of a medicated feed mill license.**

\* \* \* \* \*

(d) \* \* \*

**CATEGORY II**

Drug	Assay limits percent <sup>1</sup>	Type A	Type B maximum (100x)	Assay limits percent <sup>1</sup>	Type B/C <sup>2</sup>
Florfenicol	*	90-110	Swine feed: n/a Catfish feed: n/a	*	Swine feed: 85-115 Catfish feed: 80-110

<sup>1</sup>Percent of labeled amount.

<sup>2</sup>Values given represent ranges for either Type B or Type C medicated feeds. For those drugs that have two range limits, the first set is for a Type B medicated feed and the second set is for a Type C medicated feed. These values (ranges) have been assigned in order to provide for the possibility of dilution of a Type B medicated feed with lower assay limits to make Type C medicated feed.

\* \* \* \* \*

3. In § 558.261, revise paragraphs (a) and (c)(2); redesignate paragraph (e)(1) as paragraph (e)(2); and add new paragraphs (c)(3) and (e)(1) to read as follows:

**§ 558.261 Florfenicol.**

(a) *Specifications.* Type A medicated articles containing florfenicol in the following concentrations:

(1) 40 grams per kilogram for use as in paragraph (e)(1) of this section.

(2) 500 grams per kilogram for use as in paragraph (e)(2) of this section.

\* \* \* \* \*

(c) \* \* \*  
 (2) The expiration date of veterinary feed directives (VFDs) for florfenicol medicated feeds:

(i) For catfish must not exceed 15 days from the date of issuance;

(ii) For swine must not exceed 90 days from the date of issuance.

(3) VFDs for florfenicol shall not be refilled.

\* \* \* \* \*

(e) \* \* \*

(1) *Swine—(i) Amount.* Feed 182 grams per ton of feed (200 parts per million) continuously as the sole ration for 5 days.

(ii) *Indications for use.* For the control of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Streptococcus suis*, and *Bordetella bronchiseptica* in groups of swine in buildings experiencing an outbreak of SRD.

(iii) *Limitations.* The safety of florfenicol on swine reproductive performance, pregnancy, and lactation